Differences in predominant enhancement mechanisms of superparamagnetic iron oxide and ultrasmall superparamagnetic iron oxide for contrast-enhanced portal magnetic resonance angiography: Preliminary results of an animal study original investigation

Friedrich D Knollmann, Johannes C. Böck, Kerstin Rautenberg, Jürgen Beier, Wolfgang Ebert, Roland Felix

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

RATIONALE AND OBJECTIVES. To determine the effect of particle size of superparamagnetic iron oxide (SPIO) contrast agents on magnetic resonance angiography of the portal venous system. METHODS. We studied eight beagle dogs by a T1-weighted 3D turbo-gradient echo magnetic resonance (MR) angiography sequence (TE 4 milliseconds, TR 11 milliseconds, flip angle 25°, coronal imaging plane) before and after administration of either Resovist (SHU555A), a superparamagnetic iron oxide contrast agent with a mean particle size of 60 nm and a relaxivity ratio R2/R1 of approximately 7, or a new ultrasmall superparamagnetic iron oxide (USPIO) contrast agent with a mean particle size of approximately 20 nm and a R2/R1 ratio of approximately 2. Images were acquired on a 1.5-T MR body scanner. Both agents were injected as a peripheral bolus of 40 μmol Fe/kg body weight. Repeated scans were acquired before, immediately after, and 10, 20, 30, and 40 minutes after administration of the agent. RESULTS. After administration of Resovist, portal venous signal increased to 237% of control immediately after injection, while hepatic parenchymal signal intensity decreased to 86% of control. The maximal CNR increase to 177% was achieved immediately after injection of the agent. After USPIO, portal venous signal increased to 401% of the precontrast value immediately after injection, while hepatic parenchymal signal intensity also increased to 131% of control at this time. Hepatic signal then decreased progressively to 49% of control after 40 minutes. The maximal CNR increase to 326% was achieved 10 minutes after injection of the agent. CONCLUSIONS. It is concluded that superparamagnetic iron oxide particles of different sizes have different R2/R1 ratios and, consequently, different mechanisms of contrast improvement in T1-weighted portal MR angiograms.

Original languageEnglish (US)
Pages (from-to)637-643
Number of pages7
JournalInvestigative Radiology
Volume33
Issue number9
DOIs
StatePublished - Sep 1998
Externally publishedYes

Fingerprint

Magnetic Resonance Angiography
Particle Size
Contrast Media
Injections
Liver
Magnetic Resonance Spectroscopy
Portal System
Angiography
Body Weight
Dogs
ferric oxide
ferumoxtran-10
ferumoxides

Keywords

  • Contrast agents
  • Iron oxides
  • Magnetic resonance angiography
  • Particle size
  • Portal vein

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Cite this

@article{22c4760948d94db9b9a54938dc46dc46,
title = "Differences in predominant enhancement mechanisms of superparamagnetic iron oxide and ultrasmall superparamagnetic iron oxide for contrast-enhanced portal magnetic resonance angiography: Preliminary results of an animal study original investigation",
abstract = "RATIONALE AND OBJECTIVES. To determine the effect of particle size of superparamagnetic iron oxide (SPIO) contrast agents on magnetic resonance angiography of the portal venous system. METHODS. We studied eight beagle dogs by a T1-weighted 3D turbo-gradient echo magnetic resonance (MR) angiography sequence (TE 4 milliseconds, TR 11 milliseconds, flip angle 25°, coronal imaging plane) before and after administration of either Resovist (SHU555A), a superparamagnetic iron oxide contrast agent with a mean particle size of 60 nm and a relaxivity ratio R2/R1 of approximately 7, or a new ultrasmall superparamagnetic iron oxide (USPIO) contrast agent with a mean particle size of approximately 20 nm and a R2/R1 ratio of approximately 2. Images were acquired on a 1.5-T MR body scanner. Both agents were injected as a peripheral bolus of 40 μmol Fe/kg body weight. Repeated scans were acquired before, immediately after, and 10, 20, 30, and 40 minutes after administration of the agent. RESULTS. After administration of Resovist, portal venous signal increased to 237{\%} of control immediately after injection, while hepatic parenchymal signal intensity decreased to 86{\%} of control. The maximal CNR increase to 177{\%} was achieved immediately after injection of the agent. After USPIO, portal venous signal increased to 401{\%} of the precontrast value immediately after injection, while hepatic parenchymal signal intensity also increased to 131{\%} of control at this time. Hepatic signal then decreased progressively to 49{\%} of control after 40 minutes. The maximal CNR increase to 326{\%} was achieved 10 minutes after injection of the agent. CONCLUSIONS. It is concluded that superparamagnetic iron oxide particles of different sizes have different R2/R1 ratios and, consequently, different mechanisms of contrast improvement in T1-weighted portal MR angiograms.",
keywords = "Contrast agents, Iron oxides, Magnetic resonance angiography, Particle size, Portal vein",
author = "Knollmann, {Friedrich D} and B{\"o}ck, {Johannes C.} and Kerstin Rautenberg and J{\"u}rgen Beier and Wolfgang Ebert and Roland Felix",
year = "1998",
month = "9",
doi = "10.1097/00004424-199809000-00019",
language = "English (US)",
volume = "33",
pages = "637--643",
journal = "Investigative Radiology",
issn = "0020-9996",
publisher = "Lippincott Williams and Wilkins",
number = "9",

}

TY - JOUR

T1 - Differences in predominant enhancement mechanisms of superparamagnetic iron oxide and ultrasmall superparamagnetic iron oxide for contrast-enhanced portal magnetic resonance angiography

T2 - Preliminary results of an animal study original investigation

AU - Knollmann, Friedrich D

AU - Böck, Johannes C.

AU - Rautenberg, Kerstin

AU - Beier, Jürgen

AU - Ebert, Wolfgang

AU - Felix, Roland

PY - 1998/9

Y1 - 1998/9

N2 - RATIONALE AND OBJECTIVES. To determine the effect of particle size of superparamagnetic iron oxide (SPIO) contrast agents on magnetic resonance angiography of the portal venous system. METHODS. We studied eight beagle dogs by a T1-weighted 3D turbo-gradient echo magnetic resonance (MR) angiography sequence (TE 4 milliseconds, TR 11 milliseconds, flip angle 25°, coronal imaging plane) before and after administration of either Resovist (SHU555A), a superparamagnetic iron oxide contrast agent with a mean particle size of 60 nm and a relaxivity ratio R2/R1 of approximately 7, or a new ultrasmall superparamagnetic iron oxide (USPIO) contrast agent with a mean particle size of approximately 20 nm and a R2/R1 ratio of approximately 2. Images were acquired on a 1.5-T MR body scanner. Both agents were injected as a peripheral bolus of 40 μmol Fe/kg body weight. Repeated scans were acquired before, immediately after, and 10, 20, 30, and 40 minutes after administration of the agent. RESULTS. After administration of Resovist, portal venous signal increased to 237% of control immediately after injection, while hepatic parenchymal signal intensity decreased to 86% of control. The maximal CNR increase to 177% was achieved immediately after injection of the agent. After USPIO, portal venous signal increased to 401% of the precontrast value immediately after injection, while hepatic parenchymal signal intensity also increased to 131% of control at this time. Hepatic signal then decreased progressively to 49% of control after 40 minutes. The maximal CNR increase to 326% was achieved 10 minutes after injection of the agent. CONCLUSIONS. It is concluded that superparamagnetic iron oxide particles of different sizes have different R2/R1 ratios and, consequently, different mechanisms of contrast improvement in T1-weighted portal MR angiograms.

AB - RATIONALE AND OBJECTIVES. To determine the effect of particle size of superparamagnetic iron oxide (SPIO) contrast agents on magnetic resonance angiography of the portal venous system. METHODS. We studied eight beagle dogs by a T1-weighted 3D turbo-gradient echo magnetic resonance (MR) angiography sequence (TE 4 milliseconds, TR 11 milliseconds, flip angle 25°, coronal imaging plane) before and after administration of either Resovist (SHU555A), a superparamagnetic iron oxide contrast agent with a mean particle size of 60 nm and a relaxivity ratio R2/R1 of approximately 7, or a new ultrasmall superparamagnetic iron oxide (USPIO) contrast agent with a mean particle size of approximately 20 nm and a R2/R1 ratio of approximately 2. Images were acquired on a 1.5-T MR body scanner. Both agents were injected as a peripheral bolus of 40 μmol Fe/kg body weight. Repeated scans were acquired before, immediately after, and 10, 20, 30, and 40 minutes after administration of the agent. RESULTS. After administration of Resovist, portal venous signal increased to 237% of control immediately after injection, while hepatic parenchymal signal intensity decreased to 86% of control. The maximal CNR increase to 177% was achieved immediately after injection of the agent. After USPIO, portal venous signal increased to 401% of the precontrast value immediately after injection, while hepatic parenchymal signal intensity also increased to 131% of control at this time. Hepatic signal then decreased progressively to 49% of control after 40 minutes. The maximal CNR increase to 326% was achieved 10 minutes after injection of the agent. CONCLUSIONS. It is concluded that superparamagnetic iron oxide particles of different sizes have different R2/R1 ratios and, consequently, different mechanisms of contrast improvement in T1-weighted portal MR angiograms.

KW - Contrast agents

KW - Iron oxides

KW - Magnetic resonance angiography

KW - Particle size

KW - Portal vein

UR - http://www.scopus.com/inward/record.url?scp=0342699623&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0342699623&partnerID=8YFLogxK

U2 - 10.1097/00004424-199809000-00019

DO - 10.1097/00004424-199809000-00019

M3 - Article

C2 - 9766048

AN - SCOPUS:0342699623

VL - 33

SP - 637

EP - 643

JO - Investigative Radiology

JF - Investigative Radiology

SN - 0020-9996

IS - 9

ER -